Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Portfolio Pulse from
Regulus Therapeutics announced positive updates from its ADPKD program for Farabursen (RGLS8429), including promising Phase 1b trial results and a successful FDA meeting for Phase 3 trial planning.
January 29, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regulus Therapeutics reported positive interim results from its Phase 1b trial for Farabursen (RGLS8429) in ADPKD, showing a dose response and reduced kidney volume growth. The FDA has agreed on key components for a Phase 3 trial, potentially accelerating approval.
The positive clinical trial results and successful FDA meeting are significant milestones for Regulus Therapeutics, indicating potential for accelerated approval. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100